( en | de | ru )

 

Disambiguation

From post

копироватьудалитьдобавить публикацию в буфер
A biological definition of Burkitt's Lymphoma from transcriptional and genomic profiling

, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , и . The New England Journal of Medicine, 354 (23): 2419--2430 (2006)

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed.

Hans Konrad Müller-Hermelink

Hans Konrad Müller-Hermelink

Maya Müller-Hermelink

Hans Konrad Müller

Nele Ulrike Müller-Hermelink

 

Другие публикации лиц с тем же именем

Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study, , , , , , , , , и 8 other автор(ы). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 (27): 4548–4554 (2009)Microarray-based genomic profiling reveals novel genomic aberrations in follicular lymphoma which associate with patient survival and gene expression status, , , , , , , , , и 18 other автор(ы). Genes, chromosomes & cancer, 48 (1): 39–54 (2009)Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial, , , , , , , , , и 10 other автор(ы). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 (23): 3495–3502 (2007)Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease, , , , , , , , , и 2 other автор(ы). The New England journal of medicine, 348 (24): 2386–2395 (2003)A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling, , , , , , , , , и 25 other автор(ы). The New England journal of medicine, 354 (23): 2419–2430 (2006)A biological definition of Burkitt's Lymphoma from transcriptional and genomic profiling, , , , , , , , , и 25 other автор(ы). The New England Journal of Medicine, 354 (23): 2419--2430 (2006)Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials, , , , , , , , , и 10 other автор(ы). Haematologica, 94 (11): 1569–1580 (2009)Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL, , , , , , , , , и 12 other автор(ы). Blood, 116 (23): 4916–4925 (2010)